Angiotensin Peptides and SARS-CoV-2: New Mechanistic Insights

Study Background and Research Question

The renin–angiotensin system (RAS) orchestrates cardiovascular and renal regulation through a cascade of peptide hormones, among which Angiotensin I, II, and their shorter fragments—such as Angiotensin 1/2 (1-6)—play central roles. Traditionally, research has focused on how these peptides, particularly the Asp-Arg-Val-Tyr-Ile-His hexapeptide, modulate vascular tone, aldosterone release, and hypertension (see prior reviews). However, the COVID-19 pandemic has foregrounded new mechanistic questions, specifically the potential for endogenous peptides to influence viral entry processes. SARS-CoV-2, the causative agent of COVID-19, infects cells by engaging its spike protein with several host cell receptors, including ACE2, neuropilin-1 (NRP1), and, crucially, AXL—a receptor that mediates infection in cells with low ACE2 expression.

Against this backdrop, Oliveira et al. (2025) sought to determine whether physiologically relevant angiotensin peptides modulate the binding affinity of the SARS-CoV-2 spike protein for its primary and auxiliary receptors, thereby potentially impacting viral infectivity and disease progression (reference study).

Key Innovation from the Reference Study

The pivotal innovation of the Oliveira et al. study lies in demonstrating that angiotensin peptides, including Angiotensin 1/2 (1-6), significantly enhance the binding of SARS-CoV-2 spike protein to the AXL receptor. This effect is specific: while angiotensin II (1–8) and its C-terminal truncated forms (such as Angiotensin 1/2 (1-6)) increase spike–AXL association, the longer Angiotensin I (1–10) does not. Moreover, N-terminally truncated peptides (e.g., Angiotensin IV (3–8)) exhibit even greater potency—up to a 2.7-fold increase in spike–AXL binding—suggesting a structure-activity relationship that is finely tuned by peptide sequence and modification. These findings extend the known physiological roles of angiotensin fragments into the domain of viral pathogenesis, linking RAS activity directly to SARS-CoV-2 cell entry mechanisms.

Methods and Experimental Design Insights

To dissect the peptide–receptor interactions, the authors employed antibody-based binding assays using recombinant human spike protein and the host receptors ACE2, NRP1, and AXL. A systematic panel of angiotensin peptides was tested, including:

• Full-length Angiotensin I (1–10)
• Angiotensin II (1–8)
• C-terminal truncated fragments: Angiotensin (1–7), Angiotensin 1/2 (1-6)
• N-terminal truncated fragments: Angiotensin III (2–8), Angiotensin IV (3–8), Angiotensin (2–7), Angiotensin (5–7)

Further, the research explored the impact of amino acid substitutions and post-translational modifications—specifically, substituting tyrosine at position 4 with valine and phosphorylating tyrosine 4—on spike–AXL binding affinity. Quantitative binding changes were assessed by measuring the fold-increase in spike–receptor association relative to controls.

Protocol Parameters

• Peptide incubation: Angiotensin peptides (including Angiotensin 1/2 (1-6)) were incubated with recombinant spike protein and receptors prior to binding measurement; typical concentrations ranged from 1–10 μM.
• Binding assay format: Antibody-based ELISA platforms were used to quantify spike–receptor interactions in the presence and absence of each peptide variant.
• Modification studies: Peptides with single-residue substitutions or phosphorylation at Tyr4 were synthesized and tested in parallel.
• Controls: Assays included negative (no peptide) and positive (Angiotensin II) controls to benchmark relative binding changes.

Core Findings and Why They Matter

The study’s most consequential discovery is that several angiotensin fragments, most notably Angiotensin 1/2 (1-6), can nearly double the binding of SARS-CoV-2 spike protein to the AXL receptor (reference study). This enhancement is not observed for ACE2 or NRP1 with these peptides, except for Angiotensin IV, which also increased spike binding to all three receptors. The results indicate that the C-terminal and N-terminal truncations of angiotensin II retain or even amplify this effect, with sequence-specific modifications (such as Tyr4 substitution or phosphorylation) further increasing spike–AXL affinity.

From a mechanistic perspective, these findings suggest that physiological or pathological shifts in RAS activity—such as those occurring in hypertension, cardiovascular disease, or during therapeutic RAS modulation—could influence susceptibility to SARS-CoV-2 by altering the microenvironment of spike-receptor interactions. This is particularly relevant for vascular tone modulation and cardiovascular regulation studies, as the interplay between RAS peptides and viral entry may contribute to the heterogeneity of COVID-19 outcomes observed in patients with underlying cardiovascular or renal dysfunction.

Comparison with Existing Internal Articles

Earlier reviews and methodological guides have established Angiotensin 1/2 (1-6) as a core reagent for renin-angiotensin system research, valued for its precise modulation of vascular tone and reproducible performance in cardiovascular and renal function studies (see recent summary). Internal resources such as "Novel Insights for Renin-Angiotensin System Research" and "Precision Tool for Renin-Angiotensin System Analysis" have focused on its role in modulating aldosterone release, sodium retention, and blood pressure regulation. The current study complements and extends these domains by positioning angiotensin fragments at the intersection of cardiovascular and viral pathobiology. Whereas previous articles explored the peptide's impact on classical RAS targets, Oliveira et al. provide direct evidence that these fragments also participate in host–pathogen interactions, specifically in the context of SARS-CoV-2.

Limitations and Transferability

While the data robustly demonstrate that angiotensin peptides enhance spike–AXL binding in vitro, several limitations should be considered. First, the experiments were conducted using recombinant proteins and ELISA-based platforms, which while highly controlled, may not fully capture the complexity of cellular or in vivo environments. Second, the concentrations of peptides used in the assays may not directly reflect physiological or pathophysiological levels in human tissues. Third, while the link between angiotensin fragments and spike–AXL binding is clear, the downstream effects on viral infectivity, replication, and clinical outcomes remain to be elucidated. As such, these findings are highly relevant for mechanistic and translational research, but further studies are needed to establish clinical significance and inform therapeutic interventions.

Why this cross-domain matters, maturity, and limitations

The cross-domain bridge identified by Oliveira et al.—from classical RAS research to viral pathogenesis—underscores the multifaceted roles of angiotensin fragments in health and disease. This intersection is especially timely given the ongoing impact of COVID-19 and the prevalence of RAS-targeting therapies. The maturity of evidence is strong for in vitro mechanistic enhancement of spike–AXL binding but remains preliminary regarding in vivo relevance and therapeutic application. Limitations include the artificial nature of the assay systems and the need for future studies in cellular and animal models to confirm these mechanistic links and assess their impact on viral infection and disease course.

Research Support Resources

For researchers aiming to replicate or extend these findings, high-purity Angiotensin 1/2 (1-6) (SKU A1048) is available from APExBIO, featuring the validated Asp-Arg-Val-Tyr-Ile-His sequence and favorable solubility for a variety of biochemical and cell-based workflows. Detailed handling parameters and additional guidance can be found in the product information. This reagent supports rigorous investigation into both classical RAS mechanisms and emerging intersections with host–pathogen interactions. For protocol optimization and reproducibility, see also the practical guidance in "Reliable Solutions for Cardiovascular and Viral Pathogenesis Research."